- Case report
- Open Access
Granulocytic sarcoma of the small bowel, greater omentum and peritoneum associated with a CBFβ/MYH11 fusion and inv(16) (p13q22): a case report
© álvarez et al; licensee BioMed Central Ltd. 2011
- Received: 29 October 2010
- Accepted: 21 January 2011
- Published: 21 January 2011
Granulocytic sarcoma (GS) is an extramedullary disease which is composed of immature myeloid cells or myeloblasts and usually occurs in association with acute myeloid leukemia (AML), as an initial presentation or a relapse. GS has been associated with various cytogenetic abnormalities, particularly with the t(8;21) translocation and less frequently the inv(16) type.
We present a rare case of GS of the small bowel, greater omentum and peritoneum, which caused obstruction, in a patient with AML associated with a CBFβ/MYH11 fusion gene and an inv(16) (p13q22). In this patient there was only mild myeloid hyperplasia in bone marrow aspiration but molecular analysis identified a CBFβ-MYH11 fusion and inv(16) (p13;q22).
Because of its nonspecific clinical and radiologic findings, this entity can be misdiagnosed and can mimic other solid neoplasms, making it a diagnostic challenge. In a GS with no or minimal morphological changes in bone marrow aspiration it is very important to perform a cytogenetic analysis to benefit from the diagnosis and therapeutic strategy.
Myeloid sarcoma represents an extramedular tumour of myeloblasts and/or immature myeloid cells . Previous terms used to describe this entity include chloroma, extramedullary myeloid tumour, and granulocytic sarcoma (GS). Chloroma was the initial term used to describe these neoplasms, due to gross greenish appearance identified in some lesions . The World Health Organization classification of haematopoietic tumours divides myeloid sarcoma into two major categories . The more common form is GS, composed mainly of myeloblasts, neutrophils, and myeloid precursors. The less common form is monoblastic sarcoma, which is tipically composed of monoblasts and is associated with acute monoblastic leukemia. GS can occur in virtually any anatomic site, with a particular predilection for skin, bone/spine, lymph nodes, soft tissue and genitourinary tract [2, 3]. Involvement of gastrointestinal tract is uncommon (7%) and the most frequently involved region in this system is the small bowel (10%) [2, 4].
GS may present in association with acute myeloid leukemia (AML), either as an initial presentation or as a relapse. It may also signal impending blast crisis in the setting of a myeloproliferative disorder or leukemic transformation in myelodysplastic syndrome. Less commonly, it may also occur as an isolated mass in non-leukemic patients (primary GS). In this later setting, the majority of untreated patients progress to AML within 11 months [2, 5]. GS in the setting of AML occurs most frequently in acute myeloblastic leukemia with maturation (French-American-British [FAB] M2) but has also been described in the other subtypes including FAB M0, M1, M3, M4, M5, and M7 .
GS has been associated with various cytogenetic abnormalities, particularly with the t(8;21) translocation  and less frequently the inv(16) type . In cases previously reported to involve the small bowel or its mesentery there has been an association with inv(16) or the CBFβ/MYH11 fusion gene or both [7, 8].
We present a rare case of GS of the small bowel, greater omentum and peritoneum, which caused obstruction, in a patient with AML type FAB-M2 associated with a CBFβ/MYH11 fusion gene and an underlying inversion of chromosome 16, inv(16) (p13q22).
A 41-year-old man was admitted with a 5-day history of intermittent, crampy abdominal pain associated with vomiting and fever. The patient also reported a 2-month history of alternating diarrhea and constipation, abdominal distension and weight loss.
GS is a rare entity that represents a challenging diagnosis that can present clinically, radiologically, and histopathologically similar to several other processes. This disease has been reported to occur in just about every anatomic location imaginable. GS may present as either isolated or multiple lesions involving one or more organ systems, and lesions may be synchronous or metachronous. In a large series, Yamauchi and Yasuda  noted that the majority of reported cases presented as isolated masses. However, patients with multiple lesions, up to four organs systems involved at one time, were also described. In patients with GS involving the small bowel, the age of presentation varies from 8 to 69 years, with the majority occurring in male . Ileum is the most frequently involved region of the gastrointestinal tract [4, 9], while its presence in the jejunum is rare . Even more rare is the synchronous involvement of the jejunum and the greater omentum , or as in the patient reported here, who had a concomitant involvement of jejunum, greater omentum and peritoneum.
The majority of anatomical sites where GS develops are associated with little to no clinical manifestations and are discovered at autopsy . In contrast, GS in the gastrointestinal tract generally produces symptoms that are often non-specific, as abdominal pain, vomiting, fever, diarrhea, and weight loss . The patients may also present with intussusception , gastrointestinal bleeding , perforation , anasarca and chronic anemia , and obstruction [8, 11]. Initially, our patient presented with non-specific symptomatology until he was adimitted for obstruction.
Most patients with GS tend to have leukemia at presentation, or they will eventually develop leukemia. The patient reported here is one of the rare cases in which abdominal GS coincided with the onset of AML type FAB-M2 associated with a CBFβ/MYH11 fusion and inv(16) (p13;q22). In a recent review, Zhang et al  describe that until 2010, only 20 cases of GS involved with inv(16) have been reported. The chromosome karyotypes of these patients were many and varied. However, all cases had the inv(16) karyotipic abnormality or positive CBFβ/MYH11 fusion gene. AML type FAB-M2 is usually associated with t(8;21) which is more prone to infiltrate extramedullary sites than inv(16). Both of the two types of rearrangements involve the core binding factor gene. The mechanism of the occurrence of GS may be related to the deregulation of the core binding factor transcription factors involved in cell recognition and adhesion .
The wide variety of manifestations of GS often make the diagnosis very difficult; gastrointestinal involvement is very unusual and we must maintain a high index of suspicion. The diagnosis of GS can be supported with the use of multiple modalities including histochemical and immunoperoxidase stains, conventional cytogenetics, fluorescent in situ hybridization cytogenetics, and flow cytometry. These techniques are especially important in primary GS, in which a previous diagnosis of leukemia or myelodysplastic syndrome has not been made [4, 5]. The correct diagnosis can be derived with the aid of histochemical and immunoperoxidase stains such as naphtol-ASD-chloroacetate esterase, lysozime, CD34, CD117, and MPO [2, 17], as in our case. Flow cytometry also is helpful in identifying blast populations expressing stem cell (CD34), myeloid (CD13, CD33, CD117, MPO), and/or monocytic (CD11c and CD14) antigens . In our patient, a flow cytometric analysis performed on the ascitic fluid was helpful, as previously reported . Conventional cytogenetics and fluorescent in situ hybridization studies are probably most useful in identifying specific characteristics present in previous lesions as a sign of relapse or residual disease. Specific cytogenetic abnormalities most frequently associated with GS include t(8;21) and inv(16) (p13;q22) [4, 15]. Most cases of primary GS will develop AML. Although there are reports of primary GS occurring prior the diagnosis of AML [8, 11], it is very important to perform bone marrow cytogenetic in a GS before it is coined as primary GS . This fact was demonstrated in the current case report, where the patient showed only mild myeloid hyperplasia in bone marrow aspiration but molecular analysis identified a CBFβ-MYH11 fusion and inv(16) (p13;q22). Hence, it might not be appropriate to label a GS as primary when bone marrow examination shows no or minimal morphological changes but specific cytogenetic abnormalitiy to a particular disease such as CBFβ-MYH11.
GS can be difficult to diagnose, especially in cases that are aleukemic, and it may be mistaken for diffuse large cell lymphoma of the small bowel . Therefore, the diagnostician should maintain a high index of suspicion when encountering an atypical presentation mimicking lymphoma, lymphocytic infiltrate, or autoimmune disease . Timely accurate diagnosis and subclassification is important as prompt treatment with appropriate therapy may prevent the development of a leukemic phase and improve complete response rates and overall survival . In the treatment of GS, systemic chemotherapy, surgical resection, radiotherapy, peripheral stem cell/bone marrow transplantation, or a combination of these approaches are used on a case-by-case basis. However, it remains uncertain what constitutes the best treatment in GS-associated AML patients. Surgery is not usually the first option, and it is only indicated in the event of complications like bleeding or obstruction , as in our patient. Although only a few large series comparing treatment modalities of GS are available in the literature [2, 20], systemic chemotherapy for AML seems to offer the most benefit. In this regard, Lan et al  have pointed out that early diagnosis with biopsy and early chemotherapy seems to improve survival outcome but local radiation or surgery seems to improve symptoms but does not influence survival outcomes.
Leukemia with inv(16) (p13;q22) translocation or CBFβ-MYH11 fusion gene is a especial type which is usually sensitive to chemotherapy and carries a better prognosis than some other leukemia types. It has also been reported that GS reduced the overall survival in t(8;21) AML cases  but GS with inv(16) seems not to affect clinical outcome . Further investigation is still necessary to identify the clinical significance of inv(16) of GS and to choose appropriate therapeutic strategy. Activating FLT3 mutations occur in approximately 40% of cytogenetically normal AML patients and the most frequent activating mutations is FLT3-ITD, whose presence is associated with resistence to chemotherapy and inferior outcome . This unfavorable prognostic factor was found in our patient.
We describe a rare case of abdominal GS in a patient with AML associated with a CBFβ/MYH11 fusion and inv(16) (p13q22). Because of its nonspecific clinical and radiologic findings, this entity can be misdiagnosed and can mimic other solid neoplasms, making it a diagnostic challenge. In a GS with no or minimal morphological changes in bone marrow aspiration it is very important to perform a cytogenetic analysis. Although all patients should be treated with chemotherapy for AML, radiotherapy and surgery are indicated in appropriate clinical settings.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Brunning RD, Matutes E, Flandrin G, Vardiman J, Bennett J, Head D, Harris NL: Tumours of haematopoietic and lymphoid tissues. In World Heath Organization Classification. Edited by: Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon, France: IARC Press; 2001:104–5.Google Scholar
- Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE, Bennett JM: Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer 1981, 48:1426–37.PubMedView ArticleGoogle Scholar
- Meiss JM, Butler JJ, Osborne , Manning JT: Granulocytic sarcoma in non-leukemic patients. Cancer 1986, 58:2697–709.View ArticleGoogle Scholar
- Kohl SK, Aoun P: Granulocytic sarcoma of the small intestine. Arch Pathol Lab Med 2006, 130:1570–4.PubMedGoogle Scholar
- Yamauchi K, Yasuda M: Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer 2002, 94:1739–46.PubMedView ArticleGoogle Scholar
- Tallman MS, Hakimian D, Shaw JM, Lissner GS, Russel EJ, Variakojis D: Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 1993, 11:690–7.PubMedGoogle Scholar
- Xavier SG, Fagundes EM, Hassan R, Bacchi C, Conchon M, Tabak DG, Spector N, Zalcberg IR: Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature. Leuk Res 2003, 27:1063–6.PubMedView ArticleGoogle Scholar
- Kumar B, Bommana V, Irani F, Kasmani R, Mian A, Mahajan K: An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma. Q J Med 2009, 102:491–3.Google Scholar
- Choi EK, Ha HK, Park SH, Lee SJ, Jung SE, Kim KW, Lee SS: Granulocytic sarcoma of bowel: CT findings. Radiology 2007, 243:752–9.PubMedView ArticleGoogle Scholar
- Palanivelu C, Rangarajan M, Senthilkumar R, Annapoorni S: Laparoscopic management of an obstructing granulocytic sarcoma of the jejunum causing intussusception in a nonleukemic patient: Report of a case. Surg Today 2009, 39:606–9.PubMedView ArticleGoogle Scholar
- Ioannidis O, Cheva A, Kakoutis E, Rafail S, Kotronis A, Chatzopoulos S, Makrantonakis N: Primary myeloid sarcoma of the jejunum and greater omentum causing small intestine obstruction. Acta Gastro-Enterologica Belgica 2009, 72:369–72.PubMedGoogle Scholar
- Miksanek T, Reyes CV, Semkiw Z, Molnar ZV: Granulocytic sarcoma of the peritoneum. CA-A Cancer J Clin 1983, 33:40–3.View ArticleGoogle Scholar
- Priebe WM, Senecal FM: Gastric chloroma associated with upper gastrointestinal tract bleeding. Gastrointestinal Endosc 1991, 37:482–4.View ArticleGoogle Scholar
- Khan MY, Hussein KK, Walter MG, Hasan MK, Kern W, Kharfan-Dabaja MA: Granulocytic sarcoma presenting with malignant anasarca in a patient with secondary acute myeloid leukemia. Int J Hematol 2004, 79:250–2.PubMedView ArticleGoogle Scholar
- Zhang XH, Zhang R, Yanfen L: Granulocytic sarcoma of abdomen in acute myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: Case report and review of literature. Leuk Res 2010, 34:958–61.PubMedView ArticleGoogle Scholar
- McKenna M, Arnold C, Catherwood MA, Humphreys MW, Cuthbert RJG, Bueso-Ramos C, McManus DT: Myeloid sarcoma of the small bowel associated with a CBFβ-MYH11 and inv(16) (p13q22): a case report. J Clin Pathol 2009, 62:757–9.PubMedView ArticleGoogle Scholar
- Audouin J, Comperat E, Le Tourneau A, Camilleri-Broët S, Adida C, Molina T, Diebold J: Myeloid sarcoma: Clinical and morphologic criteria useful for diagnosis. Int J Surg Pathol 2003, 11:271–82.PubMedView ArticleGoogle Scholar
- Kuan JW, Pathmanathan R, Chan KM, Tan SM: Aleukemic bcr-abl positive granulocytic sarcoma. Leuk Res 2009, 33:1574–7.PubMedView ArticleGoogle Scholar
- Holloman D, Eberts P, Clark C, Lewin D, Lazarchick J, Stuart R, Comerford L: Extensive involvement of the gastrointestinal tract by a de novo presentation of the monoblastic type of myeloid sarcoma: a case report of a rare entity that is often misdiagnosed. Am J Med Sci 2009, 338:513–6.PubMedView ArticleGoogle Scholar
- Byrd JC, Edenfield WJ, Shields DJ, Dawson NA: Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 1995, 13:1800–16.PubMedGoogle Scholar
- Lan TY, Lin DT, Tien HF, Yang RS, Chen CY, Wu K: Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol 2009, 122:238–46.PubMedView ArticleGoogle Scholar
- Kaiser S, Schlenk RF, Correa Londono M, Breitenbuecher F, Wittke K, Du J, Groner S, Späth D, Krauter J, Ganser A, Döhner H, Fischer T, Döhner K, the German-Austrian AML Study Group (AMLSG): Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009, 114:2386–92.View ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.